Optimism Of Cannabis Patients Creates More Demand For Phytiva Brand Of Cannabinoid Solutions As Illinois And New Hampshire Take Key Legislative Steps Toward Legalization Of Medical Cannabis
DALLAS, March 8, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health solutions through its Phytiva brand product lines is pleased that in the last two days, medical cannabis bills have easily advanced out of key committees to full votes in both the Illinois General Assembly and the New Hampshire House of Representatives. These actions toward providing safe access to medical cannabis for people with unmet medical needs in both Illinois with House Bill 0030 and New Hampshire with House Bill 442-FN continue the trend of state-by-state recognition of the medical value of cannabis and cannabinoids.
Currently 18 states and the District of Columbia have enacted laws which approve and regulate the use medical cannabis, two of which are considering expansion of existing law. In addition to Illinois and New Hampshire, another 17 states have pending legislation to enact a form of legal protection for medicinal cannabis patients. Recent national polls show that approximately 80% of Americans are in favor of medicinal cannabis legalization.
"We are incredibly encouraged that more than two-thirds of U.S. states have adopted laws or are formally considering bills to help patients in need of medical cannabis for their ailments. We commend the most recent bipartisan developments in Illinois and New Hampshire. As more and more jurisdictions provide legal safe access frameworks, the Company intends to enter these markets, not only in the United States but also abroad, with its Phytiva brand product lines," stated Robert Kane, President and CEO of X-Change Corp.
About Phytiva Brand Product LinesPhytiva expects to develop and launch various innovative product lines. The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a cannabinoid based product line, utilizing the unique and potent benefits of cannabinoids. Phytiva's revolutionary formulations target not just the symptom, but also the cause. Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies for human ailments.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts